Use of Mesoporous Silica SBa-15 and SBa-16 in Association of Outer Membrane Vesicles - OMV from Neisseria meningitidis
Danilo A Alves, Ives B Mattos, Luciana M Hollanda and Marcelo Lancellotti*
LABIOTEC - Biotechnology Laboratory, Department of Biochemistry, Institute of Biology CP6109, University of Campinas - UNICAMP 13083-970, Campinas, SP, Brazil
- *Corresponding Author:
- Marcelo Lancellotti
Department of Biochemistry, Institute of Biology CP6109
State University of Campinas – UNICAMP
13083-970, Campinas, SP, Brazil
Tel: +55 19 35 21 61 50
Fax: +55 19 35 21 61 29
E-mail: [email protected]
Received date: May 18, 2013; Accepted date: July 27, 2013; Published date: July 31, 2013
Citation: Alves DA, Mattos IB, Hollanda LM, Lancellotti M (2013) Use of Mesoporous Silica SBa-15 and SBa-16 in Association of Outer Membrane Vesicles - OMV from Neisseria meningitidis. J Vaccines Vaccin 4:196. doi: 10.4172/2157-7560.1000196
Copyright: © 2013 Alves DA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Outer membrane vesicles or OMV are nanoparticles released in culture medium during meningococcal growth resulting from evaginations of the outer cellular membrane and have been indicated as potential target for vaccine production. This study aimed to analyze the use of Neisseria meningitidis B2443, as vaccine using a semi-solid fermentation process based in ultrafiltration for the isolation these OMV and also verify the effect of the mesouporous silica (SBA-15 and SBA-16). The OMV preparation follow the method without the ultracentrifugation whose was subtituted by ultrafiltration method using a nitrocelulosis filtre showing a pore of 0.025 μm. For the detection of antibodies production were used the immunological method of ELISA, and serum bactericidal effect using sera from immunized mices with OMV and adjuvant inorganic nanoparticles. Also, the use of citotocity test were performed based in the neutral red uptake for safety of the associated vaccin use in NIH-3T3 cell line. It was compared to OMV production of strains of N. meningitidis strains B2443 and C2135. The results showed that different strains of N. meningitidis have OMVs kinetics of production of different time and quantity. The use of SBA-15 and SBA-16 as adujvant at 250 μg for each mice was enough to induce an increase of vaccinal (for other serogroups) capacity same using a only OMV extracted from strains B2443. The study showed that the methodology used for the production of OMV is advantageous from the point of view of quantity and cost and use of this biologic nanoparticle. Both mesoporous silica SBa15 and SBa16 used in this work were capable to increase de recognition of antibody against different strains fo N. meningitidis showed using the OMV extracted from an only vaccinal strain.